SV2B

Summary

SV2B (synaptic vesicle glycoprotein 2B, HGNC:16874) is a protein-coding gene on chromosome 15q26.1, encoding Synaptic vesicle glycoprotein 2B (Q7L1I2). Probably plays a role in the control of regulated secretion in neural and endocrine cells.

This gene encodes a member of the synaptic vesicle proteins 2 (SV2) family and major facilitator superfamily of proteins. This protein and other members of the family are localized to synaptic vesicles and may function in the regulation of vesicle trafficking and exocytosis. Studies in mice suggest that the encoded protein may act as a protein receptor for botulinum neurotoxin E in neurons, and that this protein may be important for the integrity of the glomerular filtration barrier. This gene shows reduced expression in areas of synaptic loss in the hippocampus of human temporal lobe epilepsy patients.

Source: NCBI Gene 9899 — RefSeq curated summary.

At a glance

• GWAS associations: 9
• Clinical variants (ClinVar): 105 total
• Druggable target: yes
• MANE Select transcript: NM_001323032

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16874
Approved symbol	SV2B
Name	synaptic vesicle glycoprotein 2B
Location	15q26.1
Locus type	gene with protein product
Status	Approved
Aliases	KIAA0735, HsT19680, SLC22B2
Ensembl gene	ENSG00000185518
Ensembl biotype	protein_coding
OMIM	185861
Entrez	9899

Gene structure

Transcript identifiers

Ensembl transcripts: 15 — 12 protein_coding, 1 retained_intron, 1 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000330276, ENST00000394232, ENST00000545111, ENST00000553727, ENST00000557291, ENST00000557410, ENST00000867188, ENST00000867189, ENST00000957278, ENST00000957279, ENST00000957280, ENST00000957281, ENST00000957282, ENST00000957283, ENST00000957284

RefSeq mRNA: 11 — MANE Select: NM_001323032 NM_001167580, NM_001323031, NM_001323032, NM_001323033, NM_001323034, NM_001323036, NM_001323037, NM_001323038, NM_001323039, NM_001323040, NM_014848

CCDS: CCDS10370, CCDS53972

Canonical transcript exons

ENST00000394232 — 13 exons

Exon	Start	End
ENSE00001289941	91267555	91267643
ENSE00001290491	91258421	91258554
ENSE00001291039	91281728	91281861
ENSE00001300064	91266582	91266692
ENSE00001303687	91292369	91302565
ENSE00001303877	91284021	91284221
ENSE00001313169	91268441	91268605
ENSE00001316306	91225873	91226714
ENSE00001317674	91252369	91252520
ENSE00001322799	91289521	91289680
ENSE00001517814	91100257	91100363
ENSE00003556205	91251819	91251999
ENSE00003592238	91260320	91260409

Expression profiles

Bgee: expression breadth ubiquitous, 202 present calls, max score 99.26.

FANTOM5 (CAGE): breadth broad, TPM avg 9.4046 / max 588.4982, expressed in 281 samples.

FANTOM5 promoters (22 alternative TSS)

Promoter ID	TPM avg	Samples expressed
148554	4.8884	223
148560	0.6217	81
148549	0.5283	88
148546	0.5265	105
148544	0.3260	116
148547	0.3025	77
148557	0.2690	71
148545	0.2473	77
148552	0.2413	91
148556	0.2312	73

Top tissues by expression

290 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
middle temporal gyrus	UBERON:0002771	99.26	gold quality
Brodmann (1909) area 10	UBERON:0013541	98.88	gold quality
Brodmann (1909) area 23	UBERON:0013554	98.46	gold quality
frontal pole	UBERON:0002795	98.30	gold quality
Brodmann (1909) area 46	UBERON:0006483	98.02	gold quality
orbitofrontal cortex	UBERON:0004167	97.72	gold quality
paraflocculus	UBERON:0005351	97.49	gold quality
superior frontal gyrus	UBERON:0002661	97.35	gold quality
pons	UBERON:0000988	97.29	gold quality
postcentral gyrus	UBERON:0002581	96.86	gold quality
parietal lobe	UBERON:0001872	96.78	gold quality
lateral nuclear group of thalamus	UBERON:0002736	96.77	gold quality
cerebellar vermis	UBERON:0004720	96.53	gold quality
secondary oocyte	CL:0000655	96.30	gold quality
entorhinal cortex	UBERON:0002728	95.88	gold quality
endothelial cell	CL:0000115	95.54	gold quality
primary visual cortex	UBERON:0002436	94.69	gold quality
prefrontal cortex	UBERON:0000451	94.62	gold quality
frontal cortex	UBERON:0001870	94.38	gold quality
occipital lobe	UBERON:0002021	94.13	gold quality
substantia nigra pars compacta	UBERON:0001965	94.11	gold quality
CA1 field of hippocampus	UBERON:0003881	94.04	gold quality
cerebellum	UBERON:0002037	93.92	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	93.52	gold quality
Brodmann (1909) area 9	UBERON:0013540	93.48	gold quality
cerebellar cortex	UBERON:0002129	93.43	gold quality
cerebellar hemisphere	UBERON:0002245	93.30	gold quality
neocortex	UBERON:0001950	92.39	gold quality
right hemisphere of cerebellum	UBERON:0014890	92.30	gold quality
cerebral cortex	UBERON:0000956	91.85	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-HCAD-25	yes	87.52
E-HCAD-35	yes	62.14
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

359 targeting SV2B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-3134	100.00	66.43	777
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-1193	100.00	65.93	529
HSA-MIR-4673	100.00	66.64	1490
HSA-MIR-3064-3P	100.00	70.09	1254
HSA-MIR-574-5P	100.00	66.01	989
HSA-MIR-432-3P	100.00	67.86	705
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-548AW	99.99	72.57	3559

Literature-anchored findings (GeneRIF, showing 4)

• Synaptic vesicle protein 2 binds adenine nucleotides (PMID:18524768)
• In classical mesial temporal sclerosis 1A, the expression of SV2 isoforms is altered with a marked decrease of SV2B paralleling synaptic loss. (PMID:23617838)
• Bioinformatics analysis of potential core genes for glioblastoma. (PMID:32667033)
• Differentiation of two human neuroblastoma cell lines alters SV2 expression patterns. (PMID:33588752)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	sv2ba	ENSDARG00000057427
danio_rerio	sv2bb	ENSDARG00000060711
mus_musculus	Sv2b	ENSMUSG00000053025
rattus_norvegicus	Sv2b	ENSRNOG00000011160

Paralogs (2): SV2C (ENSG00000122012), SV2A (ENSG00000159164)

Protein

Protein identifiers

Synaptic vesicle glycoprotein 2B — Q7L1I2 (reviewed: Q7L1I2)

All UniProt accessions (1): Q7L1I2

UniProt curated annotations — full annotation on UniProt →

Function. Probably plays a role in the control of regulated secretion in neural and endocrine cells. (Microbial infection) Receptor for the C.botulinum neurotoxin type A2 (BoNT/A, botA); glycosylation is not essential but enhances the interaction. Probably also serves as a receptor for the closely related C.botulinum neurotoxin type A1.

Subunit / interactions. Interacts with SYT1 in a calcium-independent manner. Forms a complex with SYT1, syntaxin-1 and SNAP25. (Microbial infection) Interacts with C.botulinum neurotoxin type A2 (BoNT/A, botA). Interaction is improved by glycosylation of SV2.

Subcellular location. Cytoplasmic vesicle. Secretory vesicle. Synaptic vesicle membrane. Acrosome.

Post-translational modifications. N-glycosylated. The N-terminal cytoplasmic domain is phosphorylated by CK1.

Similarity. Belongs to the major facilitator superfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
Q7L1I2-1	1	yes
Q7L1I2-2	2

RefSeq proteins (11): NP_001161052, NP_001309960, NP_001309961, NP_001309962, NP_001309963, NP_001309965, NP_001309966, NP_001309967, NP_001309968, NP_001309969, NP_055663 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR005828	MFS_sugar_transport-like	Family
IPR005829	Sugar_transporter_CS	Conserved_site
IPR011701	MFS	Family
IPR020846	MFS_dom	Domain
IPR022308	SV2	Family
IPR036259	MFS_trans_sf	Homologous_superfamily
IPR055415	LD_SV2	Domain

Pfam: PF00083, PF07690, PF23894

UniProt features (35 total): topological domain 13, transmembrane region 12, modified residue 3, glycosylation site 3, chain 1, region of interest 1, splice variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

6 structures.

PDB	Method	Resolution (Å)
8UO8	ELECTRON MICROSCOPY	3.2
9F2B	ELECTRON MICROSCOPY	3.49
9F1R	ELECTRON MICROSCOPY	3.67
9F2J	ELECTRON MICROSCOPY	3.98
9F2Y	ELECTRON MICROSCOPY	4.39
9F3C	ELECTRON MICROSCOPY	5.41

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q7L1I2-F1	81.79	0.45

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (3): 33, 36, 423

Glycosylation sites (3): 441, 491, 516

Function

Pathways and Gene Ontology

Reactome pathways

9 pathways

ID	Pathway
R-HSA-5250955	Toxicity of botulinum toxin type D (botD)
R-HSA-5250968	Toxicity of botulinum toxin type A (botA)
R-HSA-5250981	Toxicity of botulinum toxin type F (botF)
R-HSA-5250992	Toxicity of botulinum toxin type E (botE)
R-HSA-1643685	Disease
R-HSA-168799	Neurotoxicity of clostridium toxins
R-HSA-5339562	Uptake and actions of bacterial toxins
R-HSA-5663205	Infectious disease
R-HSA-9824439	Bacterial Infection Pathways

MSigDB gene sets: 235 (showing top): AP1_01, BENPORATH_ES_WITH_H3K27ME3, MYOGENIN_Q6, MODULE_255, GOCC_SECRETORY_GRANULE, GOBP_REGULATION_OF_EXOCYTOSIS, MODULE_317, GOBP_NEUROTRANSMITTER_TRANSPORT, CROONQUIST_NRAS_SIGNALING_UP, GOBP_VESICLE_MEDIATED_TRANSPORT, GOBP_CELL_CELL_SIGNALING, GOBP_REGULATION_OF_VESICLE_MEDIATED_TRANSPORT, MODULE_66, GOBP_EXOCYTOSIS, AP1_Q4_01

GO Biological Process (5): neurotransmitter transport (GO:0006836), chemical synaptic transmission (GO:0007268), regulation of presynaptic cytosolic calcium ion concentration (GO:0099509), regulation of synaptic vesicle exocytosis (GO:2000300), transmembrane transport (GO:0055085)

GO Molecular Function (2): transmembrane transporter activity (GO:0022857), protein binding (GO:0005515)

GO Cellular Component (7): acrosomal vesicle (GO:0001669), plasma membrane (GO:0005886), synaptic vesicle (GO:0008021), membrane (GO:0016020), synaptic vesicle membrane (GO:0030672), cytoplasmic vesicle (GO:0031410), synapse (GO:0045202)

Reactome top-level categories

Rollup of top-5 pathways:

Category	Pathways
Neurotoxicity of clostridium toxins	4
Uptake and actions of bacterial toxins	1
Bacterial Infection Pathways	1
Disease	1
Infectious disease	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
transport	2
presynapse	2
anterograde trans-synaptic signaling	1
regulation of cytosolic calcium ion concentration	1
neuron cellular homeostasis	1
synaptic vesicle exocytosis	1
regulation of neurotransmitter secretion	1
regulation of regulated secretory pathway	1
cellular process	1
transporter activity	1
transmembrane transport	1
binding	1
secretory granule	1
membrane	1
cell periphery	1
exocytic vesicle	1
cellular anatomical structure	1
synaptic vesicle	1
exocytic vesicle membrane	1
cytoplasm	1
intracellular vesicle	1
cell junction	1

Protein interactions and networks

STRING

1660 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SV2B	GP2	P55259	900
SV2B	SYT1	P21579	762
SV2B	IMMT	Q16891	679
SV2B	STX1B	P61266	621
SV2B	SYNPR	Q8TBG9	558
SV2B	SYNGR1	O43759	557
SV2B	SNAP25	P13795	523
SV2B	SSX2IP	Q9Y2D8	500
SV2B	VAMP2	P19065	493
SV2B	SLC17A7	Q9P2U7	484
SV2B	SYT2	Q8N9I0	484
SV2B	GRIK4	Q16099	484
SV2B	CAMK2A	Q9UQM7	481
SV2B	GAD1	Q99259	473
SV2B	INS	P01308	473

IntAct

9 interactions, top by confidence:

A	B	Type	Score
SV2B	HSFY1	psi-mi:“MI:0915”(physical association)	0.560
MAPT	SHTN1	psi-mi:“MI:0914”(association)	0.350
ZNF778	LRP4	psi-mi:“MI:0914”(association)	0.350
SV2B	C15orf61	psi-mi:“MI:0914”(association)	0.350

BioGRID (107): HSFY1 (Two-hybrid), SV2B (Affinity Capture-MS), SV2B (Affinity Capture-Western), SV2B (Affinity Capture-Western), SV2B (Affinity Capture-RNA), SV2B (Affinity Capture-MS), SV2B (Affinity Capture-RNA), SV2B (Affinity Capture-MS), SV2B (Affinity Capture-MS), AARS2 (Affinity Capture-MS), ABHD12 (Affinity Capture-MS), ACSL4 (Affinity Capture-MS), AGK (Affinity Capture-MS), AHSA1 (Affinity Capture-MS), AP3M1 (Affinity Capture-MS)

ESM2 similar proteins: A1C5W7, A1DG37, A2QFJ9, A2X8A7, A2Y8U6, A6ZIQ8, A7KAM9, B8AF63, B8AT51, B8BDK8, B9FMX4, E9EFH8, F4IKF6, G2WS43, O22216, O80605, Q02563, Q0CL24, Q0JAW2, Q0VA82, Q29397, Q2UMJ2, Q2V4F9, Q3TMP8, Q496J9, Q4R4X3, Q5EAU0, Q5F361, Q5R4L9, Q63564, Q658H5, Q65X70, Q69ZS6, Q6EPQ3, Q6GPQ3, Q6YK44, Q7L0J3, Q7L1I2, Q8BG39, Q8BH31

Diamond homologs: A0R5K5, A2RJJ9, B4TES5, D0CCT2, E8ZB61, O08966, O15245, O24723, O30513, O52733, P0A0J4, P0A0J5, P0A0J6, P0A0J7, P0A4K4, P0A4K5, P0AE24, P0AE25, P45598, P77228, P77589, P94493, Q02563, Q21455, Q29397, Q3E9A0, Q43975, Q4R4X3, Q51955, Q5EXK5, Q5HHX4, Q5R4L9, Q63089, Q69ZS6, Q6FFF7, Q6GBD5, Q6GIU7, Q7L0J3, Q7L1I2, Q9I6Q3

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

105 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	96
Likely benign	3
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

2903 predictions. Top by Δscore:

Variant	Effect	Δscore
15:91251816:CAG:C	acceptor_loss	1.0000
15:91251817:A:AG	acceptor_gain	1.0000
15:91251817:AG:A	acceptor_gain	1.0000
15:91251817:AGG:A	acceptor_gain	1.0000
15:91251818:G:GA	acceptor_gain	1.0000
15:91251818:GG:G	acceptor_gain	1.0000
15:91251818:GGG:G	acceptor_gain	1.0000
15:91251818:GGGA:G	acceptor_gain	1.0000
15:91251818:GGGAT:G	acceptor_gain	1.0000
15:91252367:A:AG	acceptor_gain	1.0000
15:91252368:G:GG	acceptor_gain	1.0000
15:91252368:GTATT:G	acceptor_gain	1.0000
15:91252521:G:C	donor_loss	1.0000
15:91252522:T:A	donor_loss	1.0000
15:91260308:T:TA	acceptor_gain	1.0000
15:91260309:G:A	acceptor_gain	1.0000
15:91266573:A:AG	acceptor_gain	1.0000
15:91266574:C:G	acceptor_gain	1.0000
15:91266578:TCA:T	acceptor_loss	1.0000
15:91266579:CAG:C	acceptor_loss	1.0000
15:91266580:A:AC	acceptor_loss	1.0000
15:91266580:A:AG	acceptor_gain	1.0000
15:91266580:AG:A	acceptor_gain	1.0000
15:91266581:G:GT	acceptor_gain	1.0000
15:91266581:GG:G	acceptor_gain	1.0000
15:91266581:GGT:G	acceptor_gain	1.0000
15:91266581:GGTT:G	acceptor_gain	1.0000
15:91266581:GGTTT:G	acceptor_gain	1.0000
15:91266689:GCAG:G	donor_gain	1.0000
15:91266691:AGGT:A	donor_loss	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000012802 (15:91291038 A>G), RS1000013619 (15:91263147 C>G), RS1000028282 (15:91217229 A>G), RS1000035269 (15:91126131 C>A), RS1000036142 (15:91301605 G>A,C), RS1000063435 (15:91235396 A>C), RS1000090759 (15:91132386 T>C), RS1000094578 (15:91107590 C>A,T), RS1000116448 (15:91170011 C>G,T), RS1000123240 (15:91169329 C>G,T), RS1000140873 (15:91258010 C>G), RS1000146999 (15:91258720 C>G,T), RS1000150062 (15:91153900 G>A), RS1000160713 (15:91210361 G>A,T), RS1000162769 (15:91296051 G>A)

Disease associations

OMIM: gene MIM:185861 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

9 associations (top):

Study	Trait	p-value
GCST000274_16	Metabolite levels	2.000000e-07
GCST002491_23	Age-related hearing impairment	6.000000e-06
GCST004030_27	Primary sclerosing cholangitis	2.000000e-06
GCST005790_36	Rosacea symptom severity	7.000000e-06
GCST007740_29	Iris color (a* coordinate)	7.000000e-07
GCST007741_13	Iris color (b* coordinate)	5.000000e-07
GCST008822_4	Neuritic plaque	3.000000e-06
GCST009391_151	Metabolite levels	9.000000e-06
GCST010273_6	Gout (normal type)	7.000000e-07

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0009180	rosacea severity measurement
EFO:0009764	eye colour measurement
EFO:0006798	neuritic plaque measurement
EFO:0010483	gentisic acid measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4665594 (PROTEIN FAMILY)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

23 total (human), top 23 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression	2
terbufos	increases methylation	1
sulforaphane	decreases expression	1
butyraldehyde	increases expression	1
S-(1,2-dichlorovinyl)cysteine	affects cotreatment, decreases expression, affects response to substance, increases expression	1
arsenic disulfide	decreases expression	1
CGP 52608	affects binding, increases reaction	1
abrine	increases expression	1
licochalcone B	decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Acetaminophen	decreases expression	1
Benzo(a)pyrene	affects methylation, increases methylation	1
Fonofos	increases methylation	1
Estradiol	decreases expression	1
Lead	affects expression	1
Lipopolysaccharides	increases expression, affects cotreatment, decreases expression, affects response to substance	1
Parathion	increases methylation	1
Plant Extracts	affects cotreatment, decreases expression	1
Valproic Acid	increases expression	1
Aflatoxin B1	decreases methylation	1
Saquinavir	affects response to substance	1
Okadaic Acid	decreases expression	1
Acrylamide	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer